1. Home
  2. APRE

as 05-29-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Founded: 2006 Country:
United States
United States
Employees: N/A City: DOYLESTOWN
Market Cap: 28.2M IPO Year: 2019
Target Price: $15.50 AVG Volume (30 days): 31.0K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.32 EPS Growth: N/A
52 Week Low/High: $2.78 - $8.85 Next Earning Date: 05-14-2024
Revenue: $963,800 Revenue Growth: N/A
Revenue Growth (this year): 4.93% Revenue Growth (next year): -33.33%

APRE Daily Stock ML Predictions

Stock Insider Trading Activity of Aprea Therapeutics Inc. Common stock (APRE)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Hamill John P. APRE SrVP/CFO/Prin Fin & Acct Ofcr Mar 13 '24 Buy $7.29 1,010 $7,362.90 15,503 SEC Form 4
Seizinger Bernd R. APRE Director Mar 13 '24 Buy $7.29 6,860 $50,009.40 33,685 SEC Form 4
HENNEMAN JOHN B III APRE Director Mar 13 '24 Buy $7.29 6,860 $50,009.40 8,139 SEC Form 4
Gilad Oren APRE President, CEO Mar 13 '24 Buy $7.29 2,000 $14,580.00 324,770 SEC Form 4

Share on Social Networks: